HAVCR1 and type 2 diabetes mellitus: In a post-hoc analysis of an RCT, dapagliflozin significantly reduced albuminuria in patients with T2D, and changes in albuminuria were correlated with the reduction in eGFR, as well as with the decrease in urinary tubular marker-kidney injury molecule-1 (KIM-1) (53).